Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Invested Capital: 2020-2021

Historic Return on Invested Capital for Silence Therapeutics (SLN) over the last 5 years, with Dec 2024 value amounting to 0.83%.

  • Silence Therapeutics' Return on Invested Capital was N/A to 0.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.99%, marking a year-over-year change of. This contributed to the annual value of 0.83% for FY2024, which is 184.00% up from last year.
  • Per Silence Therapeutics' latest filing, its Return on Invested Capital stood at 0.83% for FY2024, which was up 68.94% from 2.66% recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Return on Invested Capital peaked at 0.83% during FY2024, and registered a low of 4.64% during FY2021.
  • Moreover, its 3-year median value for Return on Invested Capital was 2.66% (2023), whereas its average is 2.22%.
  • Per our database at Business Quant, Silence Therapeutics' Return on Invested Capital plummeted by 247bps in 2021 and then surged by 184bps in 2024.
  • Silence Therapeutics' Return on Invested Capital (MRY) stood at 2.17% in 2020, then plummeted by 114bps to 4.64% in 2021, then soared by 32bps to 3.17% in 2022, then increased by 16bps to 2.66% in 2023, then soared by 69bps to 0.83% in 2024.
  • Its Return on Invested Capital was 0.83% in FY2024, compared to 2.66% in FY2023 and 3.17% in FY2022.